Posts

Hengrui, Kailera’s GLP‑1 Pill Posts Encouraging Efficacy but High Side Effect Rates in Late‑Stage China Trials

on

ADA: AZ’s oral GLP‑1 shows competitive efficacy in phase 2, setting stage for pivotal program

on

FDA Approves Novo Nordisk's Awiqli: First Once-Weekly Basal Insulin for Type 2 Diabetes

on

Lilly's Retatrutide Achieves 16.8% Weight Loss and A1C Reductions in Phase 3 Diabetes Trial, Comparable to Mounjaro

on

Lilly's Triple-G Retatrutide Achieves 16.8% Weight Loss and A1C Reductions in Phase 3 Type 2 Diabetes Trial

on

Insulet, Abbott, and Dexcom Present Type 2 Diabetes Technology Advances at ATTD 2026

on

Pfizer Secures Exclusive China Rights to Sciwind's Approved GLP-1 Drug Ecnoglutide in $495M Deal

on

AstraZeneca's Oral GLP-1 Obesity Pill Succeeds in Phase 2 Trials Amid Broader Portfolio Expansion

on

Jesper Høiland Joins Alva Therapeutics' Board of Directors

on

Lilly's Oral GLP-1, Orforglipron, Achieves Two New Clinical Wins in Type 2 Diabetes

on

Eli Lilly Withdraws $1.9B Phase 2b Obesity Trial Before Launching Enrollment

on

Sparrow Pharmaceuticals Raises $95M Series B for Midstage Diabetes Study

on

Lilly's Mounjaro Shows Strong Results in Youth Type 2 Diabetes, Paving Way for Expansion

on

Eli Lilly's Oral GLP-1 Orforglipron Outperforms Semaglutide in Diabetes and Weight Loss Trials

on

Lilly to Seek Global Approval for GLP-1 Pill After Obesity and Diabetes Trial Success

on

Lilly's Mounjaro Matches Cardiovascular Benefit of Trulicity in Landmark Trial, Paving Way for Expanded Approval

on

BrightGene's Dual GLP-1/GIP Agonist BGM0504 Shows Promise in Phase 2 Diabetes and Obesity Trials at ADA25

on